1[1]Ghosh P. The role of hyaluronic acid (hyaluroman)in bealth and dis-ease: interactions with cells, cartilage and components of synovial fluid.Clinic and Experimental Rheumutology, 1994; 12: 75
2[2]Scott JE. Secondary structure in hyaluronan solutions: chemical andbiological implication. In: Evered D, Whelm J, eds. The biology ofhyaluronan, Chichester:John Wiley, 1989:6～9
3[3]Balazs EA, Denlinger JL. Viscosupplementation:a new concept in thetreatment of osteoarthritis. J Rheumatol, 1993; 39 (Suppl): 3
4曾庆馀.骨性关节炎[M].6版.北京:人民卫生出版社,2004:939-944.
5卢世璧.实用骨科学[M].2版.北京:人民军医出版社,1993:1438-1442.
6Amiel D, Toyoguchi T, Kobayashi K, et al. Long-term effect of sodium hyaluronate (Hyalgan) on osteoarthritis progression in a rabbit model. Osteoarthritis Cart, 2003, 11: 636-643.
7Le Graverand MP, Eggerer J, Vignon E, et al. Assessment of specific mRNA levels in cartilage regions in a lapine model of osteoarthritis. J Orthop Res, 2002, 20: 535-544.
8Bluteau G, Conrozier T, Mathieu P, et al. Matrix metalloprotease1,-3,-13 and aggrecanase-1 and -2 are differentially expressed in experimental osteoarthritis. Biochim Biophys Acta, 2001, 1526:147-158.
9Bluteau G, Gouttenoire J, Conrozier T, et al. Differential gene expression analysis in a rabbit model of osteoarthritis induced by anterior cruciate ligament (ACL) section. Biorheology, 2002, 39:247-258.
10Mallein-Pelletier J, McCollum R, Fujimoto N, et al. Excess of metalloproteases over tissue inhibitor of metalloprotease may contribute to cartilage degradation in osteoarthritis and rheumatoid arthritis. Lab Invest, 1994, 70: 807-815.
1Ma H, Joo CW. Structure and mechanical properties of jute polylactic acid biodegradable composites[J]. Journal of Com posite Materials,2011,45(14):1 451 1 460.
2DiJtzmann S, Martin KD, Sobottka S, et al. ()pen vs retrac- tor endoscopic in situ decompression of the ulnar nerve in cu bital tunnel syndrome: A retrospective cohort study [J]. Neurosurgery, 2013, 72(4).- 605 614.
